Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $7.11M fell 14.4% year over year, behind the +4.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 13.2% from the prior quarter. Over 3 fiscal years it compounded at +9.7% a year.

Context

  • Selling, general & admin amounted to 1125.1% of revenue in FY2025, up 1047.6 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $1.09M (-96.6%) for the fiscal year ending Dec 2026, a slowdown from the +4.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.11M-13.2% QoQ
Last fiscal yearDec 2025
$31.47M+4.5% YoY
LTMMar 2026
$30.27M+4.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.4%-93.0%-78.6 pp
1 year+4.5%-96.6%-101.0 pp
3-year CAGR+9.7%+25.3%+15.7 pp
5-year CAGR+83.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
31.47M USD
Year-over-year change
+4.5%
4-year CAGR
+10.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.4% is the 8th highest of 9, against a peer median of +28.1%.
  • Selling, general & admin amounts to 1705.2% of revenue for RNAC, versus a peer median of 102.8%.
RNAC Competitors
Selling, General & Admin for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$52.43M USD+32.8%+31.8%102.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$30.27M USD+4.4%+9.7%1705.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$26.99M USD+11.1%+24.6%82.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$24.19M USD+23.5%+3.4%41000.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$23.69M USD+2.7%+2.7%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$20.02M USD———
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$17.83M USD+52.6%+62.5%—
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$16.97M USD+137.1%+72.2%—
MDWDMediWound Ltd.LTM Mar 2026$14.41M USD+9.9%+10.3%99.5%
Peer median (excluding RNAC) —+28.1%+28.2%102.8%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.